Oxford BioDynamics said it has entered into an initial collaboration with a "major" US biopharmaceutical company to advance the discovery and development of treatments for abnormal wound healing responses, leading to fibrosis.
Fibrosis is a pathological feature of most chronic inflammatory diseases, which can affect nearly every tissue in the body, the company said. If left to progress, it eventually leads to organ malfunction and possibly death.
"This new collaboration is further evidence of broad adoption of our validated proprietary technology EpiSwitch for practical use in highly challenging therapeutic development programmes," chief executive Christian Hoyer Millar said.
At 8:32am: (LON:OBD) Oxford Biodynamics Plc share price was +4.88p at 238.38p